drugset / Trial / NCT07623460
Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
Phase 2
Not yet recruiting
30 enrolled
Stuthi Perimbeti
Exelixis · collabPenn State Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center single arm phase II study of zanzalintinib after Pluvicto in chemotherapy-naïve mCRPC. Subjects will receive zanzalintinib 60mg orally (PO) once daily. Zanzalintinib may continue until evidence of radiographic progression, intolerable adverse events, or withdrawal of consent. Two interim analyses will be performed; a safety interim analysis to be performed for the first 5 evaluable subjects, and a futility interim analysis to be performed for the first 15 evaluable subjects.
Timeline
- Start
- 2026-09
- Primary completion
- 2028-09
- Completion
- 2031-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanzalintinib | Small molecule | 60 mg | Oral |